Background
Amarin Pharma developed Vascepa, a drug containing icosapent ethyl that the FDA approved for two indications: treating severe hypertriglyceridemia (the “SH indication,” approved in 2012) and reducing cardiovascular risk in hypertriglyceridemia patients already taking statins (the “CV indication,” approved in 2019). Amarin holds method-of-use patents covering the CV indication.
Hikma Pharmaceuticals, a generic manufacturer, obtained FDA approval for generic icosapent ethyl with a “skinny label” — an abbreviated label that carved out the patented CV indication and included only the SH indication. The FDA assigned Hikma’s product an “AB” therapeutic-equivalence rating to Vascepa when used according to its labeling. Every state permits or requires pharmacists to substitute AB-rated generics for brand-name drugs.
Amarin sued Hikma for actively inducing infringement of its CV-indication patents under 35 U.S.C. §271(b), pointing to a combination of statements on Hikma’s skinny label, its patient information leaflet, its website, and its press releases. The District of Delaware granted Hikma’s motion to dismiss. The Federal Circuit reversed, concluding it was “at least plausible that a physician could read” Hikma’s statements “as an instruction or encouragement to” infringe.
The Court’s Holding
In a unanimous opinion authored by Justice Jackson, the Supreme Court reversed the Federal Circuit. The Court held that Amarin failed to state a claim for active inducement because it did not plausibly allege that Hikma took “active steps” — that is, “purposeful, culpable expression and conduct” — designed to encourage doctors to prescribe its generic for the patented CV indication.
The Court clarified that the relevant question is not whether doctors could plausibly read Hikma’s statements as instructions to infringe, but whether Hikma actively encouraged infringing use. Applying this standard, the Court found that several of Hikma’s challenged statements had an “obvious alternative explanation”: compliance with the law or standard industry practice. Hikma’s label retained information about a clinical study only because statute requires a generic label to be identical to the brand label except for the carved-out use. Describing a drug as the “generic equivalent” of the brand-name comparator is normal industry practice, not an inducement to infringe.
The Court further held that mere omissions — such as the skinny label’s failure to include the CV-indication Limitation of Use or the press releases’ failure to specify that Hikma’s approved use was limited to the SH indication — cannot support an inducement claim because active inducement requires affirmative conduct, not “mere omissions, inactions, or nonfeasance.” Hikma’s remaining statements were too vague to plausibly constitute purposeful encouragement of infringement.
Key Takeaways
- A generic manufacturer’s compliance with FDA labeling requirements and standard industry practices — such as describing a product as a “generic equivalent” — cannot form the basis of an induced-infringement claim, even if a physician might interpret those statements as encouraging off-patent-label use.
- Omissions in a skinny label (failing to affirmatively disclaim a patented use) are legally insufficient to establish active inducement; §271(b) requires affirmative steps to encourage infringement.
- The Federal Circuit’s “could a physician plausibly read this as encouragement” standard was too permissive; courts must instead ask whether the manufacturer actively designed its communications to encourage infringing use.
Why It Matters
This decision provides significant protection for the generic pharmaceutical industry’s use of skinny labels — the primary mechanism by which generics enter markets where the brand drug retains patents on some but not all indications. By holding that routine regulatory compliance and standard marketing language cannot support inducement claims, the Court resolves a circuit split that had created uncertainty about whether generic manufacturers could safely launch under carved-out labels at all.
For brand-name manufacturers, the decision narrows the scope of induced-infringement claims significantly. Going forward, brand companies will need to identify specific, affirmative statements by the generic manufacturer that go beyond legal compliance and industry norms — a much heavier pleading burden. For IP practitioners, the opinion clarifies the boundary between patent protection and drug-pricing competition in the Hatch-Waxman framework, reinforcing the congressional design that generics should be able to enter markets for non-patented uses without undue litigation risk.